4D Molecular Therapeutics (FDMT) Return on Sales (2020 - 2025)
4D Molecular Therapeutics (FDMT) has disclosed Return on Sales for 6 consecutive years, with 631.72% as the latest value for Q3 2025.
- On a quarterly basis, Return on Sales rose 1398228.0% to 631.72% in Q3 2025 year-over-year; TTM through Sep 2025 was 1742.84%, a 669316.0% increase, with the full-year FY2024 number at 4345.7%, down 434085.0% from a year prior.
- Return on Sales was 631.72% for Q3 2025 at 4D Molecular Therapeutics, up from 3639.8% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 1698.47% in Q4 2023 to a low of 49650.0% in Q4 2024.
- A 5-year average of 4168.07% and a median of 123.95% in 2023 define the central range for Return on Sales.
- Peak YoY movement for Return on Sales: crashed -5134847bps in 2024, then skyrocketed 1398228bps in 2025.
- 4D Molecular Therapeutics' Return on Sales stood at 272.57% in 2021, then surged by 92bps to 21.94% in 2022, then surged by 7841bps to 1698.47% in 2023, then tumbled by -3023bps to 49650.0% in 2024, then skyrocketed by 99bps to 631.72% in 2025.
- Per Business Quant, the three most recent readings for FDMT's Return on Sales are 631.72% (Q3 2025), 3639.8% (Q2 2025), and 3431.36% (Q1 2025).